2. Academic Validation
  3. Anti-inflammatory agents design via the fragment hybrid strategy in the discovery of compound c1 for treating ALI and UC

Anti-inflammatory agents design via the fragment hybrid strategy in the discovery of compound c1 for treating ALI and UC

  • Eur J Med Chem. 2025 Feb 25:289:117431. doi: 10.1016/j.ejmech.2025.117431.
Mi Guo 1,  Yu Zou 1,  Ke Dong 2,  Nan Huang 2,  Zhichao Chen 2,  Chenhui Sun 3,  Pan Chen 2,  Qi Chen 2,  Luxiao Zhu 2,  Yuehua Lv 4,  Kaixin Zhang 3,  Miao Jiang 4,  Yitian Gao 5,  Young-Chang Cho 6,  Qidong Tang 7,  Guang Liang 8,  Di Wu 9
Affiliations

Affiliations

  • 1 Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, China; Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, 325001, China.
  • 2 Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, China.
  • 3 Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, 325001, China; Zhejiang Provincial Key Laboratory for Water Environment and Marine, Biological Resources Protection, College of Life and Environmental Science, Wenzhou University, Wenzhou, 325035, China.
  • 4 Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, 325001, China.
  • 5 Zhejiang Provincial Key Laboratory for Water Environment and Marine, Biological Resources Protection, College of Life and Environmental Science, Wenzhou University, Wenzhou, 325035, China.
  • 6 College of Pharmacy, Chonnam National University, Gwangju, 61186, South Korea.
  • 7 Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, China; Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, 325001, China. Electronic address: tangqidongcn@126.com.
  • 8 Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, China; Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, 325001, China; School of Pharmaceutical Sciences, Hangzhou Medical College, Hangzhou, 310053, China. Electronic address: wzmcliangguang@163.com.
  • 9 Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, China. Electronic address: wudi2017@wmu.edu.cn.
PMID: 40037062 DOI: 10.1016/j.ejmech.2025.117431
Abstract

Acute lung injury (ALI) and ulcerative colitis (UC) are common inflammatory diseases with high mortality rates and unsatisfactory cure rates. Studies have indicated that inhibiting the expression and release of inflammatory factors holds potential for the treatment of inflammatory diseases. In this study, we designed and synthesized 28 derivatives of 6,7-disubstituted-4-cis-cyclohexanequinazoline and assessed their anti-inflammatory activities in mouse macrophages RAW264.7, J774A.1, and human monocyte THP-1 cell lines. Among them, derivative c1 was found to significantly inhibit the expression and release of pro-inflammatory cytokines interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) induced by lipopolysaccharide (LPS) in the three cells mentioned above. It was also demonstrated that c1 could bind to IRAK4 and affect the expression of these two inflammatory factors by inhibiting the activation of the MAPK pathway. Furthermore, in vivo experiments revealed that c1 effectively ameliorated LPS-induced ALI and dextran sulfate sodium (DSS)-induced UC. Additionally, we evaluated the pharmacokinetic properties and in vivo safety of c1. Therefore, our research has identified the 6,7-disubstituted-4-cis-cyclohexanequinazoline derivative c1 exhibiting promising anti-inflammatory effects as a prospective anti-inflammatory drug candidate.

Keywords

Acute lung injury; IRAK4; Inflammation; Quinazoline derivatives; Ulcerative colitis.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z